Covid vaccine: Glenmark’s phase-3 clinical trial of Favipiravir shows positive response

Favipiravir is a broad spectrum oral antiviral drug that selectively inhibits RNA-dependent RNA polymerase (RdRp) and the viral replication phase of SARS-CoV-2, and is being studied in multiple ongoing international clinical trials.

from The Financial Express https://ift.tt/3jrNrM1
https://ift.tt/eA8V8J FE Bureau